A Phase 3 interventional study of Brexpiprazole in Agitation Associated With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 55 Years to 89 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Dementia by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Otsuka Holdings Co., Ltd..
Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is one of 8 in phase 3, and was the 11th registered.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
Browse Dementia studies →None of the 11 studies in Dementia by Otsuka Holdings Co., Ltd. is open now. The open studies under Dementia, anywhere →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 55 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 377 across the 10 interventional studies, 450 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy of brexpiprazole.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Brexpiprazole
Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
Also known as: OPC-34712
The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)
This trial enrolled subjects rolled over from Trial 331-102-00088, and the safety of brexpiprazole when administered for a maximum of 24 weeks (including the treatment period of Trial 331-102-00088) was evaluated.
Time frame: From baseline to week 14
Mean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing
The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.
Time frame: Baseline and 14 weeks after dosing
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing.
The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.
Time frame: Baseline and 14 weeks after dosing.
Clinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing
The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.
Time frame: 14 weeks after dosing.
| Milestone | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| Started | 102 | 62 |
| Completed | 73 | 44 |
| Not completed | 29 | 18 |
| Withdrew: Adverse event | 20 | 14 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Physician decision | 5 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Bedridden all day and required full assistance for excretion, meals and change of clothes | 0 | 1 |
| Withdrew: Withdrawal by legal representative | 3 | 0 |
This trial enrolled subjects rolled over from Trial 331-102-00088, and the safety of brexpiprazole when administered for a maximum of 24 weeks (including the treatment period of Trial 331-102-00088) was evaluated.
| Percentage of percipitante | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) | 90.2 | 90.3 |
The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.
| Units on a scale | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| Mean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing | -2.5 ± 9.9 | -6.4 ± 9.3 |
The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.
| Units on a scale | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing. | -0.2 ± 0.8 | -0.4 ± 1.1 |
The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.
| Units on a scale | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| Clinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing | 3.1 ± 1.2 | 2.7 ± 1.1 |
Collected over Adverse events were monitored from signing of the informed consent form through 35 days after last dose of study drug (Up to approximately Week 19). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ROLLOVER BREX | 0/102 (0%) | 7/102 (6.9%) | 90/102 (88.2%) |
| ROLLOVER PLACEBO | 1/62 (1.6%) | 4/62 (6.5%) | 55/62 (88.7%) |
| Event | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| Pneumonia aspirationInfections and infestations | 1/102 | 2/62 |
| Gait disturbanceGeneral disorders | 2/102 | 0/62 |
| PneumoniaInfections and infestations | 1/102 | 1/62 |
| Femur fractureInjury, poisoning and procedural complications | 1/102 | 1/62 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/102 | 1/62 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/102 | 0/62 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/102 | 0/62 |
| Blood creatine phosphokinase increasedInvestigations | 1/102 | 0/62 |
| Muscle rigidityMusculoskeletal and connective tissue disorders | 1/102 | 0/62 |
| AkathisiaNervous system disorders | 1/102 | 0/62 |
| Event | ROLLOVER BREX | ROLLOVER PLACEBO |
|---|---|---|
| InsomniaPsychiatric disorders | 5/102 | 12/62 |
| Sedation complicationNervous system disorders | 7/102 | 9/62 |
| SomnolenceNervous system disorders | 13/102 | 7/62 |
| FallInjury, poisoning and procedural complications | 12/102 | 4/62 |
| Skin abrasionInjury, poisoning and procedural complications | 11/102 | 2/62 |
| Decreased appetiteMetabolism and nutrition disorders | 5/102 | 6/62 |
| Extrapyramidal disorderNervous system disorders | 3/102 | 6/62 |
| Muscle rigidityMusculoskeletal and connective tissue disorders | 9/102 | 4/62 |
| BradykinesiaNervous system disorders | 9/102 | 3/62 |
| ContusionInjury, poisoning and procedural complications | 8/102 | 5/62 |
This trial was conducted in 164 participants in Japan.
| Age, Categorical(Participants) | ROLLOVER BREX | ROLLOVER PLACEBO | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 2 | 8 |
| >=65 years | 96 | 60 | 156 |
| Age, Continuous(years) | ROLLOVER BREX | ROLLOVER PLACEBO | Total |
|---|---|---|---|
| Mean | 79.0 ± 6.8 | 80.2 ± 6.9 | 79.5 ± 6.8 |
| Sex: Female, Male(Participants) | ROLLOVER BREX | ROLLOVER PLACEBO | Total |
|---|---|---|---|
| Female | 65 | 36 | 101 |
| Male | 37 | 26 | 63 |
| Race/Ethnicity, Customized(Participants) | ROLLOVER BREX | ROLLOVER PLACEBO | Total |
|---|---|---|---|
| Asian | 102 | 62 | 164 |
| Region of Enrollment(participants) | ROLLOVER BREX | ROLLOVER PLACEBO | Total |
|---|---|---|---|
| Japan | 102 | 62 | 164 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Nov 2018 to primary completion in Dec 2021, 36 months.
Results were first posted in Sep 2024, 2 years 9 months after primary completion.
Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 36 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Co., Ltd. →